alendronate has been researched along with Neointima in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Neointima: The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Généreux, P | 1 |
Chernin, G | 1 |
Assali, AR | 1 |
Peruga, JZ | 1 |
Robinson, SD | 1 |
Schampaert, E | 1 |
Bagur, R | 1 |
Mansour, S | 1 |
Rodés-Cabau, J | 1 |
McEntegart, M | 1 |
Gerber, R | 1 |
L'Allier, P | 1 |
de Silva, R | 1 |
Daneault, B | 1 |
Aggarwal, SK | 1 |
Džavík, V | 1 |
Ozan, MO | 1 |
Ben-Yehuda, O | 1 |
Maehara, A | 1 |
Stone, GW | 1 |
Jonas, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention[NCT02645799] | Phase 2 | 270 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for alendronate and Neointima
Article | Year |
---|---|
Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial.
Topics: Alendronate; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; | 2022 |